Treatment and Visual Outcomes in Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy: A Cohort Study
We report on the systemic treatment response of seven children with ADNIV treated with methotrexate, infliximab, and tocilizumab. None were able to control disease. Further studies are needed to understand long-term outcomes and the utility of systemic immunosuppression.
Authors
- Grant S. Schulert (ORCID: https://orcid.org/0000-0001-5923-7051)
- Ilaria Maccora (ORCID: https://orcid.org/0000-0001-6418-3254)
- Megan Quinlan‐Waters
- Jared J. Ebert (ORCID: https://orcid.org/0000-0003-4001-3001)
- Jennifer Huggins
- Sheila T. Angeles‐Han (ORCID: https://orcid.org/0000-0002-9552-6464)
- Sunil K. Srivastava (ORCID: https://orcid.org/0000-0002-0398-8806)
- Alexandra Duell
- Tiffany Nguyen
- Cameron C. Sapp
- Arjun B. Sood
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Cleveland Clinic (US)
- University of Louisville (US)
- Retina Associates (US)
- Meyer Children's Hospital (IT)
- Cincinnati Eye Institute (US)
- Cleveland Eye Clinic (US)
- University of Florence (IT)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1080/09273948.2024.2401146
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health